Publications: Miss Christine Hughes
Zardab M, Balarajah V, Banerjee A, Stasinos K, Saad A, Imrali A, Hughes C, Roberts R et al.
(
2022
)
.
Differentiating Ductal Adenocarcinoma of the Pancreas from Benign Conditions Using Routine Health Records: A Prospective Case-Control Study
.
Cancers
vol.
15
,
(
1
)
Goulart MR, Watt J, Siddiqui I, Lawlor RT, Imrali A, Hughes C, Saad A, ChinAleong J et al.
(
2021
)
.
Pentraxin 3 is a stromally-derived biomarker for detection of pancreatic ductal adenocarcinoma
.
npj Precision Oncology
vol.
5
,
(
1
)
Kocher HM, Basu B, Froeling FE, Sarker D, Slater S, Carlin D, deSouza NM, De Paepe KN et al.
(
2020
)
.
STARPAC clinical trial
.
Pancreatology
vol.
20
,
(
8
)
Imrali A, Hughes CS, Coetzee AS, Delvecchio FR, Saad A, Roberts R, Chelala C, ChinAleong J et al.
(
2020
)
.
Validation of a Novel, FlashâFreezing Method: Aluminum Platform
.
Current Protocols Essential Laboratory Techniques
vol.
21
,
(
1
)
Kocher HM, Basu B, Froeling FEM, Sarker D, Slater S, Carlin D, deSouza NM, De Paepe KN et al.
(
2020
)
.
Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer
.
Nature Communications
vol.
11
,
(
1
)
Hughes CS, ChinAleong J-A, Kocher HM
(
2020
)
.
CRABP2 and FABP5 expression levels in diseased and normal pancreas
.
Annals of Diagnostic Pathology
vol.
47
,
Kocher HM, Basu B, Froeling FEM, Sarker D, Slater S, Carlin D, Coetzee C, de Souza N et al.
(
2019
)
.
700P STAR-PAC: Phase I clinical trial repurposing all trans retinoic acid (ATRA) as stromal targeting agent in a novel drug combination for pancreatic cancer
.
Annals of Oncology
vol.
30
,